These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 17317439

  • 21. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
    Calabria M, Geroldi C, Lussignoli G, Sabbatini F, Zanetti O.
    Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
    [Abstract] [Full Text] [Related]

  • 22. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
    López-Pousa S, Olmo JG, Franch JV, Estrada AT, Cors OS, Nierga IP, Gelada-Batlle E.
    Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
    [Abstract] [Full Text] [Related]

  • 23. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration.
    Rozzini L, Chilovi BV, Conti M, Bertoletti E, Delrio I, Trabucchi M, Padovani A.
    Int J Geriatr Psychiatry; 2007 Dec; 22(12):1217-22. PubMed ID: 17562522
    [Abstract] [Full Text] [Related]

  • 24. Mild cognitive impairment as predictor for Alzheimer's disease in clinical practice: effect of age and diagnostic criteria.
    Visser PJ, Verhey FR.
    Psychol Med; 2008 Jan; 38(1):113-22. PubMed ID: 17451628
    [Abstract] [Full Text] [Related]

  • 25. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.
    Caballero J, Hitchcock M, Scharre D, Beversdorf D, Nahata MC.
    Clin Ther; 2006 Oct; 28(10):1695-700. PubMed ID: 17157125
    [Abstract] [Full Text] [Related]

  • 26. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.
    Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, Kavanagh S.
    Int J Geriatr Psychiatry; 2009 May; 24(5):479-88. PubMed ID: 18985627
    [Abstract] [Full Text] [Related]

  • 27. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
    Wattmo C, Wallin AK, Londos E, Minthon L.
    Gerontologist; 2011 Feb; 51(1):17-27. PubMed ID: 20562471
    [Abstract] [Full Text] [Related]

  • 28. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP.
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [Abstract] [Full Text] [Related]

  • 29. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B.
    Dement Geriatr Cogn Disord; 2008 Jan; 26(5):458-66. PubMed ID: 18984956
    [Abstract] [Full Text] [Related]

  • 30. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S, Juby A, Morelli L, Rehel B, Schecter R, EXTEND Investigators.
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [Abstract] [Full Text] [Related]

  • 31. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA, Paramadevan J, Abdullah L, Mullan M.
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [Abstract] [Full Text] [Related]

  • 32. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms.
    Amieva H, Le Goff M, Millet X, Orgogozo JM, Pérès K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF.
    Ann Neurol; 2008 Nov; 64(5):492-8. PubMed ID: 19067364
    [Abstract] [Full Text] [Related]

  • 33. Demented versus non-demented very old inpatients: the same comorbidities but poorer functional and nutritional status.
    Zekry D, Herrmann FR, Grandjean R, Meynet MP, Michel JP, Gold G, Krause KH.
    Age Ageing; 2008 Jan; 37(1):83-9. PubMed ID: 17971391
    [Abstract] [Full Text] [Related]

  • 34. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F, Portet F, Touchon J, Vellas B.
    J Nutr Health Aging; 2007 Jan; 11(4):330-7. PubMed ID: 17653493
    [Abstract] [Full Text] [Related]

  • 35. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.
    Neurology; 2007 Jul 31; 69(5):459-69. PubMed ID: 17664405
    [Abstract] [Full Text] [Related]

  • 36. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM.
    J Am Osteopath Assoc; 2005 Mar 31; 105(3):145-58. PubMed ID: 15863734
    [Abstract] [Full Text] [Related]

  • 37. Behavioral disturbances in Alzheimer's disease: a non-pharmacological therapeutic approach.
    Silvestri A, Rosano G, Zannino G, Ricca F, Marigliano V, Fini M.
    Arch Gerontol Geriatr Suppl; 2004 Mar 31; (9):379-86. PubMed ID: 15207436
    [Abstract] [Full Text] [Related]

  • 38. Drug therapy of dementia in elderly patients. A review.
    Olsen CE, Poulsen HD, Lublin HK.
    Nord J Psychiatry; 2005 Mar 31; 59(2):71-7. PubMed ID: 16195103
    [Abstract] [Full Text] [Related]

  • 39. Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort.
    Hsiung GY, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan DB, Rockwood K, Feldman HH.
    Dement Geriatr Cogn Disord; 2008 Mar 31; 25(6):483-90. PubMed ID: 18417973
    [Abstract] [Full Text] [Related]

  • 40. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R.
    Pharmacogenet Genomics; 2006 Nov 31; 16(11):771-4. PubMed ID: 17047484
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.